ClinicalTrials.gg
Drug

Gilteritinib clinical trials

Also written ASP2215 and Xospata.

studies test it
41
open now
19
in phase 3
10
first study started
2013

How each study uses gilteritinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the gilteritinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Nov 2018 · XOSPATA · NDA 211349 (FDA, Drugs@FDA)
European Union
24 Oct 2019 · Xospata · EMEA/H/C/004752 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Gilteritinib
34

Brand

Xospata
8

Development codes

ASP2215
25

Studies by the year they started

41 studies that test it; most in 2024 (7)

Studies that test gilteritinib, by start year
YearStudies
20131
20141
20154
20164
20173
20181
20195
20203
20212
20221
20232
20247
20253
20264

By phase

A phase 1/2 study counts in both.

Phase 1
22
Phase 2
18
Phase 3
10
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 21

Astellas Pharma Global Development, Inc. (15) · Institute of Hematology & Blood Diseases Hospital, China (4) · Astellas Pharma Inc (3) · M.D. Anderson Cancer Center (3) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · PrECOG, LLC. (1) · AbbVie (1) · Centre Hospitalier Universitaire de Nice (1)

Often tested with

Tested in the same studies.

Venetoclax (11) · Azacitidine (11) · Cytarabine (6) · Daunorubicin (3) · CPX-351 (3) · Ivosidenib (3) · Mitoxantrone (3) · Decitabine and cedazuridine drug combination (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test gilteritinib.

Studies

Open first, then newest update. How each study uses gilteritinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 41

See all 41 studies that test gilteritinib →

Given beside what is tested · 17 — gilteritinib is usual care or a partner of the new treatment

Codes

What other systems call gilteritinib · ClinicalTrials.gg INT000493

  • MeSH (NLM) C000609080gilteritinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 66D92MGC8MGILTERITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2105806Confirmed FDA, Wikidata
  • Wikidata Q27077802gilteritinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C116722GilteritinibOne source FDA
  • DrugBank DB12141One source Wikidata

Also registered as gilteritinib fumarate (UNII 5RZZ0Z1GJT · RxNorm 2105823).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.